These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

453 related items for PubMed ID: 22339744

  • 1. High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours.
    Hofman MS, Kong G, Neels OC, Eu P, Hong E, Hicks RJ.
    J Med Imaging Radiat Oncol; 2012 Feb; 56(1):40-7. PubMed ID: 22339744
    [Abstract] [Full Text] [Related]

  • 2. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy.
    Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J.
    J Nucl Med; 2010 Jun; 51(6):875-82. PubMed ID: 20484441
    [Abstract] [Full Text] [Related]

  • 3. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
    Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, Caplin ME.
    J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The diagnostic role of 68Ga-DOTATATE PET/CT in the detection of neuroendocrine tumours.
    Łapińska G, Bryszewska M, Fijołek-Warszewska A, Kozłowicz-Gudzińska I, Ochman P, Sackiewicz-Słaby A.
    Nucl Med Rev Cent East Eur; 2011 Mar; 14(1):16-20. PubMed ID: 21751167
    [Abstract] [Full Text] [Related]

  • 8. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.
    Sadowski SM, Neychev V, Millo C, Shih J, Nilubol N, Herscovitch P, Pacak K, Marx SJ, Kebebew E.
    J Clin Oncol; 2016 Feb 20; 34(6):588-96. PubMed ID: 26712231
    [Abstract] [Full Text] [Related]

  • 9. Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results.
    Demirci E, Ocak M, Kabasakal L, Araman A, Ozsoy Y, Kanmaz B.
    Nucl Med Commun; 2013 Aug 20; 34(8):727-32. PubMed ID: 23728519
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.
    Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, Brandau W, Bockisch A, Boy C.
    J Nucl Med; 2011 Dec 20; 52(12):1864-70. PubMed ID: 22072704
    [Abstract] [Full Text] [Related]

  • 12. Neuroendocrine tumor recurrence: diagnosis with 68Ga-DOTATATE PET/CT.
    Haug AR, Cindea-Drimus R, Auernhammer CJ, Reincke M, Beuschlein F, Wängler B, Uebleis C, Schmidt GP, Spitzweg C, Bartenstein P, Hacker M.
    Radiology; 2014 Feb 20; 270(2):517-25. PubMed ID: 24056402
    [Abstract] [Full Text] [Related]

  • 13. Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin.
    Tran K, Khan S, Taghizadehasl M, Palazzo F, Frilling A, Todd JF, Al-Nahhas A.
    Hell J Nucl Med; 2015 Feb 20; 18(1):19-24. PubMed ID: 25679074
    [Abstract] [Full Text] [Related]

  • 14. 64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients.
    Pfeifer A, Knigge U, Binderup T, Mortensen J, Oturai P, Loft A, Berthelsen AK, Langer SW, Rasmussen P, Elema D, von Benzon E, Højgaard L, Kjaer A.
    J Nucl Med; 2015 Jun 20; 56(6):847-54. PubMed ID: 25952736
    [Abstract] [Full Text] [Related]

  • 15. Optimizing Somatostatin Receptor Imaging in Patients With Neuroendocrine Tumors: The Impact of 99mTc-HYNICTOC SPECT/SPECT/CT Versus 68Ga-DOTATATE PET/CT Upon Clinical Management.
    Kunikowska J, Lewington V, Krolicki L.
    Clin Nucl Med; 2017 Dec 20; 42(12):905-911. PubMed ID: 29076910
    [Abstract] [Full Text] [Related]

  • 16. Gallium-68-dotatate PET/CT is better than CT in the management of somatostatin expressing tumors: First experience in Africa.
    Lawal IO, Ololade KO, Lengana T, Reyneke F, Ankrah AO, Ebenhan T, Vorster M, Sathekge MM.
    Hell J Nucl Med; 2017 Dec 20; 20(2):128-133. PubMed ID: 28697189
    [Abstract] [Full Text] [Related]

  • 17. Changes in biodistribution on 68Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression.
    Cherk MH, Kong G, Hicks RJ, Hofman MS.
    Cancer Imaging; 2018 Jan 24; 18(1):3. PubMed ID: 29361984
    [Abstract] [Full Text] [Related]

  • 18. Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors: the referring physician's perspective.
    Herrmann K, Czernin J, Wolin EM, Gupta P, Barrio M, Gutierrez A, Schiepers C, Mosessian S, Phelps ME, Allen-Auerbach MS.
    J Nucl Med; 2015 Jan 24; 56(1):70-5. PubMed ID: 25500825
    [Abstract] [Full Text] [Related]

  • 19. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors.
    Deppen SA, Liu E, Blume JD, Clanton J, Shi C, Jones-Jackson LB, Lakhani V, Baum RP, Berlin J, Smith GT, Graham M, Sandler MP, Delbeke D, Walker RC.
    J Nucl Med; 2016 May 24; 57(5):708-14. PubMed ID: 26769865
    [Abstract] [Full Text] [Related]

  • 20. (68)Ga-DOTATATE PET/CT in the evaluation of patients with neuroendocrine metastatic carcinoma of unknown origin.
    Alonso O, Rodríguez-Taroco M, Savio E, Bentancourt C, Gambini JP, Engler H.
    Ann Nucl Med; 2014 Aug 24; 28(7):638-45. PubMed ID: 24862238
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.